Notice of Special Interest (NOSI): Availability of Administrative and Revision Supplements to Expand Vaping Research and Understand EVALI

Notice Number: NOT-HL-19-724

Key Dates
Release Date: November 06, 2019
First Available Due Date: November 08, 2019
Expiration Date: February 28, 2020

Related Announcements

PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Issued by
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA )
National Institute of Environmental Health Sciences (NIEHS)
National Center for Advancing Translational Sciences (NCATS)

Purpose

This Notice of Special Interest (NOSI) calls for research on the causes, disease mechanisms, and long-term prognosis of individuals with electronic cigarette (e-cigarette), or vaping associated lung injury (EVALI) and related health effects of vaping. Participating Institutes and Centers announce the availability of funds for Administrative Supplements and Competitive Revisions to active funded grants to investigate research questions relevant to EVALI.

Background

As of October 29, 2019, 1,888 cases of e-cigarette, or vaping, associated lung injury (EVALI) have been reported to the Centers for Disease Control and Prevention (CDC), and 37 deaths have been attributed to this illness. All EVALI patients have a history of e-cigarette use or vaping and, while the majority report using tetrahydrocannabinol- (THC-) containing vaping products, no specific single product or substance has so far been linked to all cases.

Patients diagnosed with this illness have reported symptoms such as:

  • cough, shortness of breath, or chest pain
  • nausea, vomiting, or diarrhea
  • fatigue, fever, or weight loss

Behavioral, chemical, device-related, and biological causes remain unclear and there is no clear common pathogenesis that has been discovered. This illness may in fact have multiple causes and mechanisms. Importantly, whether EVALI represents the most severe cases of a more common and milder illness, and the long-term consequences of EVALI, remain unknown.

The CDC, the US Food and Drug Administration (FDA), state and local health departments, and other clinical and public health partners continue to investigate this outbreak and its causes. For updated information on EVALI, see: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html.

Research Objectives

To better understand the causes and pathogenic mechanisms of EVALI, the listed NIH Institutes and Centers encourage the submission of applications for Administrative Supplements and Competitive Revisions to funded and active grants that seek to explore vaping-related pulmonary injury; its etiology or etiologies; and the roles of vaping devices, constituents, aerosols, and behaviors on the development of and recovery from this illness. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of vaping. Supported research will have substantial public health impact and will inform the ongoing investigation into this illness as well as its diagnosis, treatment, and prevention.

Please note: research interests may differ depending on the awarding Institute or Center. Possible research interests include:

  • What are the constituents of e-liquids designed for vaping THC or other cannabinoids that may be causing EVALI?
  • What role do the following factors play in health outcomes from vaping, including EVALI?
    • behaviors related to e-cigarette use (including dripping and dabbing)
    • constituents in e-liquid and aerosols (such as propylene glycol, vegetable glycerin, cutting agents, flavorings, degradation products, contaminants, or other additives and toxins)
    • aerosol characteristics (such as size and patterns of lung deposition)
    • device characteristics (including electronic power and resistance). At what temperatures do e-liquid components degrade, and what are the resultant products?
  • Are there population-specific contributions for susceptibility to health effects of vaping such as EVALI; e.g. based on age, gender, pregnancy status, or comorbid psychiatric or other health conditions, such as cardiopulmonary disease? Based on current case reports, applications exploring health effects in younger populations are strongly encouraged.
  • Are there individual susceptibility factors that influence risk for developing disease after potentially causative e-cigarette exposures?
  • Are there any health effects associated with secondary or environmental exposures to e-cigarette aerosols?
  • Can informatics-based cohort discovery tools be utilized across linked electronic health record networks to identify additional cases of EVALI?
  • What are the physiological and behavioral effects, such as those relevant to EVALI, of using e-liquids containing THC or other cannabinoids in combination with those containing nicotine, either in the same mixture or in subsequent vaping sessions?
  • Are device users adjusting the properties of their devices and what is the impact of those modifications?
  • What can we learn about mechanisms involved in the development of health outcomes of vaping, including EVALI? How do the agents in e-liquids, including thermal degradation products, affect the inflammatory state of pulmonary epithelia, endothelia, or immune cells?
  • What aspects of EVALI pathology or biological response can be recapitulated and studied in cell or animal models of e-cigarette exposure?
  • What are the causes of the digestive dysfunction and fever that frequently precede pulmonary symptoms of EVALI?
  • Are there biomarkers that are predictive of EVALI development or EVALI-related health outcomes?
  • How can vaping-related health outcomes, such as EVALI, be treated?
  • What is the prognosis of EVALI patients after recovery? Is there a susceptibility to subsequent diseases and infections such as influenza?

Supplementary funds may be used for the collection of lung samples from human cohorts of individuals who vape, and/or development of novel model systems to expose animals and cells to e-cigarette aerosols and aerosol constituents.

Application and Submission Information

Applications in response to this NOSI must be submitted using one of the following target funding opportunities.

  • PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Administrative supplement work that is proposed through PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) must be within the scope of the research or training that is already supported. Active awards with project end dates in FY 2020 or later are eligible. The award may not be in terminal no cost extension or going into a no cost extension in FY2020.

Applications that propose new measures and assessment or involve a change in scope (e.g., the addition of human subjects or children to a grant that has not been previously so coded and approved) should apply through PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional). Eligible activity codes for applications to PA-18-935 are dependent upon the target IC. Table 1 lists the activity codes that will be accepted by each participating IC.

Table 1: Eligible Activity Codes by Participating IC

Activity Code

NHLBI

NIEHS

NIAID

NIDA

NCI

NCATs

P01 Research Program Projects

Yes

Yes

No

Yes

Yes

No

P30 Center Core Grants

Yes

Yes

No

Yes

Yes

No

P50 Specialized Center

Yes

Yes

No

Yes

Yes

No

R00 Research Transition Award

Yes

Yes

No

Yes

Yes

No

R01 Research Project Grant

Yes

Yes

Yes

Yes

Yes

No

R03 Small Grant Program

Yes

Yes

No

Yes

Yes

No

R15 Academic Research Enhancement Award (AREA)

Yes

Yes

No

Yes

Yes

No

R21 Exploratory/Developmental Research Grant Award

Yes

Yes

Yes

Yes

Yes

Yes

R33 Exploratory/Developmental Grants Phase II

Yes

No

No

Yes

Yes

No

R35 Outstanding Investigator Award

Yes

Yes

No

No

Yes

No

R61 Phase 1 Exploratory/Developmental Grant

Yes

No

No

Yes

Yes

No

U01 Research Project – Cooperative Agreements

Yes

Yes

No

Yes

Yes

Yes

U24 Resource-Related Research Projects – Cooperative Agreements

Yes

Yes

No

Yes

Yes

No

U54 Specialized Center- Cooperative Agreements

Yes

Yes

No

Yes

Yes

No

UG3 Exploratory/Developmental Phased Award Cooperative Agreement

Yes

No

No

Yes

Yes

No

UH3 Exploratory/Developmental Phased Award Cooperative Agreement

Yes

No

No

Yes

Yes

No

UL1 Linked Specialized Center Cooperative Agreement

Yes

No

No

Yes

Yes

Yes

UM1 Multi-Component Research Project Cooperative Agreements

Yes

No

No

Yes

Yes

No

All instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-18-591 or PA-18-935) must be followed, with the following additions:

  • The Research Strategy section of the application is limited to 6 pages.
  • Applications will be accepted on a rolling basis from November 8, 2019 through February 27, 2020 by 5:00 PM local time of the applicant organization. This NOSI expires on February 28, 2020. An application submitted in response to this NOSI that is received on February 28, 2020 or later, will be withdrawn.
  • Specific to applications that target PA-18-591 (Administrative Supplements): The process for Streamlined Submissions using the eRA Commons cannot be used for PA-18-591.
  • IMPORTANT: For funding consideration, all applicants must designate NOT-HL-19-724 in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.
  • Applications nonresponsive to the terms of this Notice will be not be considered for this initiative.

Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with a Program Officer from the appropriate Institute or Center listed on this NOSI well in advance of the grant receipt date to better determine appropriateness and interest of the awarding Institute or Center

 

Inquiries

Please direct all inquiries to:

Lisa Postow, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7843
Email: lisa.postow@nih.gov

Frederick L. Tyson, Ph.D.
National Institute of Environmental and Health Sciences (NIEHS)
Telephone: 984-287-3334
Email: tyson2@niehs.nih.gov

Patrice Becker, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone:301-761-6413
Email: patrice.becker@nih.gov

Heather Kimmel, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: heather.kimmel@nih.gov

Rachel Grana Mayne, Ph.D., MPH
National Cancer Institute (NCI)
Telephone: 240-276-5899
Email: rachel.mayne@nih.gov

Mary Purucker, M.D., Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-435-0741
Email: puruckerm@mail.nih.gov